Table Info

Table 2.

Overview of highly potent inhibitors of GLUT isoforms overexpressed in OC

GLUT inhibitors	GLUT isoforms	Clinical phase	Main cell/animal models	Effective inhibitory concentration	Reference
2-DG	GLUT1	Phase Ι clinical trials	SKOV-3/TOV21	20 mmol/L	[84, 85]
RV	GLUT1	In vitro assays	OVCAR3/OAW42	100 µmol/L	[86]
Ciglitazone	GLUT1	In vitro and in vivo assays	A2780, NSG mice	1 µmol/L	[87]
Silibinin	GLUT4	In vitro assays	SKOV-3	100–200 µmol/L	[88]
BAY-876	GLUT1	In vitro and in vivo assays	SKOV-3/OVCAR-3/A2780 patient-derived xenograft	60–180 nmol/L	[89]
STF31	GLUT1	In vitro assays	OVCAR5/TOV112D/OVCAR3	0.8–1.5 µmol/L	[51]

Declarations

Author contributions

FBA: Software, Formal analysis, Visualization, Investigation, Methodology, Writing—original draft, Writing—review & editing. ZQ: Writing—original draft, Writing—review & editing, Formal analysis, Funding acquisition, Supervision, Validation. MO: Formal analysis, Funding acquisition, Supervision, Validation, Writing—review & editing. ND: Supervision, Validation. YB: Supervision, Validation, Writing—original draft. ME: Conceptualization, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing—original draft, Writing—review & editing. RAEH: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was funded by the Moroccan Ministry of Higher Education, Scientific Research and Innovation and the OCP Foundation, APRD research program (APRD 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280–304. [DOI] [PubMed]

Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathol. 2020;76:151–6. [DOI] [PubMed]

Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654–63. Erratum in: J Clin Oncol. 2012;30:4180. [DOI] [PubMed] [PMC]

Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. Erratum in: Nature. 2012;490:298. [DOI] [PubMed] [PMC]

Warburg O. The metabolism of carcinoma cells¹. J Cancer Res. 1925;9:148–63. [DOI]

Baczewska M, Bojczuk K, Kołakowski A, Dobroch J, Guzik P, Knapp P. Obesity and energy substrate transporters in ovarian cancer—review. Molecules. 2021;26:1659. [DOI] [PubMed] [PMC]

Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011;14:443–51. [DOI] [PubMed] [PMC]

Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8. Erratum in: Trends Biochem Sci. 2016;41:287. [DOI] [PubMed] [PMC]

10.

Koppenol WH, Bounds PL. The Warburg effect and metabolic efficiency: re-crunching the numbers. Science. 2009;324:1029–33. [DOI]

11.

Desbats MA, Giacomini I, Prayer-Galetti T, Montopoli M. Metabolic plasticity in chemotherapy resistance. Front Oncol. 2020;10:281. [DOI] [PubMed] [PMC]

12.

Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–7. [DOI] [PubMed]

13.

Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16:650–62. [DOI] [PubMed]

14.

San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis. 2017;38:119–33. [DOI] [PubMed] [PMC]

15.

Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. [DOI] [PubMed] [PMC]

16.

Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, et al. Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. 2015;54:35–49. [DOI] [PubMed]

17.

Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W, et al. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget. 2015;6:40799–814. [DOI] [PubMed] [PMC]

18.

Gogola-Mruk J, Marynowicz W, Krawczyk K, Ptak A. Visfatin increases the invasive potential of ovarian granulosa tumor spheroids by reprogramming glucose metabolism. Reproduction. 2023;165:521–31. [DOI] [PubMed]

19.

Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol. 2001;18:247–56. [DOI] [PubMed]

20.

Tok K, Moulahoum H, Kocadag Kocazorbaz E, Zihnioglu F. Bioactive peptides: improving the future of diabetes therapy. Stud Nat Prod Chem. 2022;75:41–74. [DOI]

21.

Ancey PB, Contat C, Meylan E. Glucose transporters in cancer – from tumor cells to the tumor microenvironment. FEBS J. 2018;285:2926–43. [DOI] [PubMed]

22.

Chai YJ, Yi JW, Oh SW, Kim YA, Yi KH, Kim JH, et al. Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: analysis of data from The Cancer Genome Atlas. Surgery. 2017;161:188–94. [DOI] [PubMed]

23.

Hediger MA, Clémençon B, Burrier RE, Bruford EA. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med. 2013;34:95–107. [DOI] [PubMed] [PMC]

24.

Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C. Facilitated hexose transporters: new perspectives on form and function. Physiology. 2007;22:234–40. [DOI] [PubMed]

25.

Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes care. 1990;13:198–208. [DOI] [PubMed]

26.

Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713–25. [DOI] [PubMed]

27.

Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004;447:480–9. Erratum in: Pflugers Arch. 2004;448:259–60. [DOI] [PubMed]

28.

Leino RL, Gerhart DZ, van Bueren AM, McCall AL, Drewes LR. Ultrastructural localization of GLUT 1 and GLUT 3 glucose transporters in rat brain. J Neurosci Res. 1997;49:617–26. [DOI] [PubMed]

29.

Charron MJ, Brosius 3rd FC, Alper SL, Lodish HF. A glucose transport protein expressed predominately in insulin-responsive tissues. Proc Natl Acad Sci U S A. 1989;86:2535–9. [DOI] [PubMed] [PMC]

30.

Douard V, Ferraris RP. Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab. 2008;295:E227–37. [DOI] [PubMed] [PMC]

31.

Rogers S, Macheda ML, Docherty SE, Carty MD, Henderson MA, Soeller WC, et al. Identification of a novel glucose transporter-like protein—GLUT-12. Am J Physiol Endocrinol Metab. 2002;282:E733–8. [DOI] [PubMed]

32.

McVie-Wylie AJ, Lamson DR, Chen YT. Molecular cloning of a novel member of the GLUT family of transporters, SLC2A10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. Genomics. 2001;72:113–7. [DOI] [PubMed]

33.

Bilan PJ, Mitsumoto Y, Maher F, Simpson IA, Klip A. Detection of the GLUT3 facilitative glucose transporter in rat L6 muscle cells: regulation by cellular differentiation, insulin and insulin-like growth factor-I. Biochem Biophys Res Commun. 1992;186:1129–37. [DOI] [PubMed]

34.

Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53:233–56. [DOI] [PubMed]

35.

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013;16:1373–82. [DOI] [PubMed] [PMC]

36.

Zhang Q, Liu J, Lin H, Lin B, Zhu M, Li M. Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells. Explor Target Antitumor Ther. 2023;4:519–36. [DOI] [PubMed] [PMC]

37.

Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001;60:162–9. [DOI] [PubMed]

38.

Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24. [DOI] [PubMed]

39.

Wagstaff P, Kang HY, Mylott D, Robbins PJ, White MK. Characterization of the avian GLUTI glucose transporter: differential regulation of GLUT1 and GLUT3 in chicken embryo fibroblasts. Mol Biol Cell. 1995;6:1575–89. [DOI] [PubMed] [PMC]

40.

Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP, et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1*. J Biol Chem. 1999;274:20281–6. [DOI] [PubMed]

41.

Cheng JC, McBrayer SK, Coarfa C, Dalva-Aydemir S, Gunaratne PH, Carpten JD, et al. Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma. Cancer Metab. 2013;1:14. [DOI] [PubMed] [PMC]

42.

Song K, Li M, Xu XJ, Xuan L, Huang GN, Song XL, et al. HIF-1α and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev. 2014;15:1823–9. [DOI] [PubMed]

43.

Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9. [DOI] [PubMed] [PMC]

44.

Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627–33. [DOI] [PubMed]

45.

Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem. 2011;286:41600–15. [DOI] [PubMed] [PMC]

46.

Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10:611–8. [DOI] [PubMed]

47.

Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006;13:951–61. [DOI] [PubMed]

48.

Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol. 2000;79:33–7. [DOI] [PubMed]

49.

Rudlowski C, Moser M, Becker AJ, Rath W, Buttner R, Schroder W, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology. 2004;66:404–10. [DOI] [PubMed]

50.

Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep. 2007;18:361–7. [PubMed]

51.

Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, et al. Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer. 2018;18:636. [DOI] [PubMed] [PMC]

52.

Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144–50. [DOI] [PubMed]

53.

Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences*. J Biol Chem. 1995;270:29083–9. [DOI] [PubMed]

54.

Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, et al. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol. 2005;98:11–8. [DOI] [PubMed]

55.

Pizzuti L, Sergi D, Mandoj C, Antoniani B, Sperati F, Chirico A, et al. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. J Cell Physiol. 2018;233:1396–401. [DOI] [PubMed]

56.

van Der Groep P, Bouter A, Menko FH, van Der Wall E, Van Diest PJ. High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat. 2008;111:475–80. [DOI] [PubMed]

57.

Kalir T, Wang BY, Goldfischer M, Haber RS, Reder I, Demopoulos R, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer. 2002;94:1078–82. [PubMed]

58.

Cai Y, Zhai JJ, Feng BB, Duan XZ, He XJ. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor. J Obstet Gynaecol Res. 2014;40:1925–30. [DOI] [PubMed]

59.

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124–39. [DOI] [PubMed]

60.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88. [DOI] [PubMed]

61.

Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health. 2014;6:537–45. [DOI] [PubMed] [PMC]

62.

Luna A, Vilanova JC, Celso Hygino Da Cruz Jr L, Rossi SE, editors. Functional imaging in oncology: clinical applications-volume 2. Heidelberg: Springer Berlin; 2014.

63.

Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. The diagnostic value of PET/CT for primary ovarian cancer—a prospective study. Gynecol Oncol. 2007;105:145–9. [DOI] [PubMed]

64.

Caroli P, Fanti S. PET-CT of gynecological malignancies and ovarian cancer. In: Luna A, Vilanova JC, Celso Hygino Da Cruz Jr L, Rossi SE, editors. Functional imaging in oncology: clinical applications-volume 2. Heidelberg: Springer Berlin; 2014. pp. 839–50.

65.

Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun. 1998;19:97–105. [DOI] [PubMed]

66.

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase ¹⁸F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80. [PubMed]

67.

Sosna J, Esses SJ, Yeframov N, Bernstine H, Sella T, Fraifeld S, et al. Blind spots at oncological CT: lessons learned from PET/CT. Cancer Imaging. 2012;12:259–68. [DOI] [PubMed] [PMC]

68.

Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF. FDG PET/CT in oncology: “raising the bar”. Clin Radiol. 2010;65:522–35. [DOI] [PubMed]

69.

Yamamoto Y, Oguri H, Yamada R, Maeda N, Kohsaki S, Fukaya T. Preoperative evaluation of pelvic masses with combined ¹⁸F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet. 2008;102:124–7. [DOI] [PubMed]

70.

Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926–32. [DOI] [PubMed]

71.

Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, et al. Diagnostic accuracy of ¹⁸F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589–95. [DOI] [PubMed]

72.

Kobayashi H. Recent advances in understanding the metabolic plasticity of ovarian cancer: a systematic review. Heliyon. 2022;8:e11487. [DOI] [PubMed] [PMC]

73.

Miyasaka N, Kubota T. Unusually intense ¹⁸F-fluorodeoxyglucose (FDG) uptake by a mature ovarian teratoma: a pitfall of FDG positron emission tomography. J Obstet Gynaecol Res. 2011;37:623–8. [DOI] [PubMed]

74.

Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12:9. [DOI] [PubMed] [PMC]

75.

Zhou L, Liu L, Chai W, Zhao T, Jin X, Guo X, et al. Dichloroacetic acid upregulates apoptosis of ovarian cancer cells by regulating mitochondrial function. Onco Targets Ther. 2019;12:1729–39. [DOI] [PubMed] [PMC]

76.

Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. 2016;18:55. [DOI] [PubMed] [PMC]

77.

Tyagi K, Mandal S, Roy A. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: a promise towards disease remission. Biochim Biophys Acta Rev Cancer. 2021;1876:188563. [DOI] [PubMed]

78.

Baczewska M, Supruniuk E, Bojczuk K, Guzik P, Milewska P, Konończuk K, et al. Energy substrate transporters in high-grade ovarian cancer: gene expression and clinical implications. Int J Mol Sci. 2022;23:8968. [DOI] [PubMed] [PMC]

79.

Chelakkot C, Chelakkot VS, Shin Y, Song K. Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 2023;24:2606. [DOI] [PubMed] [PMC]

80.

Reckzeh ES, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1–4. ChemBioChem. 2020;21:45–52. [DOI] [PubMed] [PMC]

81.

Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, et al. Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys. 1996;35:103–11. [DOI] [PubMed]

82.

Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31–4. [DOI] [PubMed]

83.

Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res. 2006;26:356–6. [PubMed]

84.

Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2010;202:371.E1–8. [DOI] [PubMed]

85.

Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, et al. Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. Mol Carcinog. 2017;56:1164–81. [DOI] [PubMed]

86.

Vidoni C, Ferraresi A, Vallino L, Salwa A, Ha JH, Seca C, et al. Glycolysis inhibition of autophagy drives malignancy in ovarian cancer: exacerbation by IL-6 and attenuation by resveratrol. Int J Mol Sci. 2023;24:1723. [DOI] [PubMed] [PMC]

87.

Ma Y, Wang W, Idowu MO, Oh U, Wang XY, Temkin SM, et al. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. Cancers (Basel). 2019;11:33. [DOI] [PubMed] [PMC]

88.

Zhan T, Digel M, Küch EM, Stremmel W, Füllekrug J. Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem. 2011;112:849–59. [DOI] [PubMed]

89.

Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14:1295–304. Erratum in: Nat Cell Biol. 2013;15:124. [DOI] [PubMed] [PMC]

90.

Esposito A, Ferraresi A, Salwa A, Vidoni C, Dhanasekaran DN, Isidoro C. Resveratrol contrasts IL-6 pro-growth effects and promotes autophagy-mediated cancer cell dormancy in 3D ovarian cancer: role of miR-1305 and of its target ARH-I. Cancers (Basel). 2022;14:2142. [DOI] [PubMed] [PMC]

91.

Pashaei-Asl F, Pashaei-Asl R, Khodadadi K, Akbarzadeh A, Ebrahimie E, Pashaiasl M. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif Cells Nanomed Biotechnol. 2018;46:1483–7. [DOI] [PubMed]

92.

Shin SJ, Kim JY, Kwon SY, Mun KC, Cho CH, Ha E. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. Eur J Pharmacol. 2014;743:17–23. [DOI] [PubMed]

93.

Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator–activated receptor-γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer. 2007;17:418–25. [DOI] [PubMed]

94.

Kwan HT, Chan DW, Cai PCH, Mak CSL, Yung MMH, Leung THY, et al. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One. 2013;8:e53597. [DOI] [PubMed] [PMC]

95.

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3:94ra70. [DOI] [PubMed] [PMC]

96.

Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29. [DOI] [PubMed]

97.

Peng J, Cui Y, Xu S, Wu X, Huang Y, Zhou W, et al. Altered glycolysis results in drug resistant in clinical tumor therapy. Oncol Lett. 2021;21:369. [DOI] [PubMed] [PMC]

98.

Meng Y, Xu X, Luan H, Li L, Dai W, Li Z, et al. The progress and development of GLUT1 inhibitors targeting cancer energy metabolism. Future Med Chem. 2019;11:2333–52. [DOI] [PubMed]

99.

van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood. 2005;106:4034–42. [DOI] [PubMed]

100.

North PE, Mizeracki A, Mihm MC, Mrak RE. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol. 2000;19:131–7. [PubMed]

101.

Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153–5. [DOI] [PubMed]

102.

Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33. [DOI] [PubMed] [PMC]

103.

Ghimire B, Karki U, Shrotriya S, Rangarajan T, Zakalik D. Cancer risk and characteristics in older female BRCA1/2 mutation carriers. J Clin Oncol. 2023;41:10610. [DOI]

104.

Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet. 2002;32:180–4. [DOI] [PubMed]

105.

Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429–32. [DOI] [PubMed] [PMC]

106.

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, et al. Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: a window of opportunity for ovarian cancer chemoprevention. Cancer Prev Res (Phila). 2017;10:255–66. [DOI] [PubMed] [PMC]

107.

Privat M, Radosevic-Robin N, Aubel C, Cayre A, Penault-Llorca F, Marceau G, et al. BRCA1 induces major energetic metabolism reprogramming in breast cancer cells. PLoS One. 2014;9:e102438. [DOI] [PubMed] [PMC]